|

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

RECRUITINGSponsored by University of Michigan Rogel Cancer Center
Actively Recruiting
SponsorUniversity of Michigan Rogel Cancer Center
Started2025-01-23
Est. completion2031-01-23
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07096999

Summary

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* \* 177Lu-617 PSMA treatment scheduled for mCRPC

  * Clinically stable as determined by the nuclear medicine clinicians
  * Male
  * ≥ 18 years of age
  * Willing and able to provide informed consent

Exclusion Criteria:

* Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed

Conditions2

CancerMetastatic Castration-Resistant Prostate Carcinoma

Locations1 site

University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
James Pool734-615-7391jampool@med.umich.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.